Related Experiment Videos
Pediatric Hodgkin's disease--up, up, and beyond
1Department of Radiation Oncology, Stanford University Medical Center, 300 Pasteur Drive, Rm. A083, Stanford, CA 94305-5302, USA. sarah@reyes.stanford.edu
International Journal of Radiation Oncology, Biology, Physics
|August 17, 2002
Summary
Pediatric Hodgkin
Area of Science:
- Pediatric oncology
- Radiation oncology
- Hematology-oncology
Background:
- Juan A. del Regato pioneered Hodgkin's disease research, focusing on radiocurability and minimizing late treatment effects in children.
- Current combined modality therapy (low-dose radiation, chemotherapy) yields a 94% 5-year survival rate for pediatric Hodgkin's disease in the US.
Discussion:
- Advances include new pathology classifications, noninvasive staging (e.g., PET scans), and risk-stratified therapy.
- Myeloablative therapy with stem cell transplant shows promise for high-risk or relapsed cases, with a 65% 5-year survival.
- Atopy is a risk factor for pulmonary toxicity post-transplant, necessitating careful patient selection.
Key Insights:
- Risk-adapted therapy and novel agents like rituximab offer improved outcomes.
- The goal of cure without late effects is achievable for most pediatric Hodgkin's disease patients.
Outlook:
- Future research focuses on refining risk stratification and exploring targeted therapies.
- Minimizing long-term side effects remains a critical objective in pediatric Hodgkin's disease treatment.